Tadalis 10 tablet: Each tablet contains 10 mg of Tadalafil INN.
Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) enhances erectile function by increasing the amount of cGMP. Tadalafil inhibits PDE5. Because sexual stimulation is required to initiate the local release of nitric oxide, the inhibition of PDE5 by Tadalafil has no effect in the absence of sexual stimulation. The effect of PDE5 inhibition on cGMP concentration in the corpus cavernosum and pulmonary arteries is also observed in the smooth muscle of the prostate, the bladder and their vascular supply. The mechanism for reducing BPH symptoms has not been established.
For oral use. In order for Tadalafil to be effective, sexual stimulation is required.
Use in adult men
The recommended dose is 10 mg taken prior to anticipated sexual activity and without regard to food. In those patients in whom Tadalafil 10 mg does not produce an adequate effect, 20 mg might be tried. It can be taken from 30 minutes to 12 hours prior to sexual activity. Efficacy of Tadalafil may persist up to 24 hours post-dose. The maximum recommended dosing frequency is once per day.
Benign prostatic hyperplasia:
5 mg, taken at approximately the same time every day.
Erectile dysfunction with benign prostatic hyperplasia:
5 mg, taken at approximately the same time every day.
Use in elderly men:
Dosage adjustments are not required in elderly patients.
Use in men with impaired renal function:
There are no available data about the administration of doses higher than 10 mg of Tadalafil to patients with renal impairment.
Use in men with impaired hepatic function:
There are no available data about the administration of doses higher than 10 mg of Tadalafil to patients with hepatic impairment.
Use in men with diabetes:
Dosage adjustments are not required in diabetic patients.
Use in children:
Tadalafil should not be used in individuals below 18 years of age.
• Tadalafil has vasodilator properties, resulting in mild and transient decreases in blood pressure
• There is limited clinical data on the safety of Tadalafil in the following groups; if prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician:
• Patients with severe renal insufficiency
• Patients with severe hepatic insufficiency
• Tadalafil should not be administered to patients with hereditary problems of galactose intolerance.
• The safety and efficacy of combinations of Tadalafil and other treatments for erectile dysfunction have not been studied. Therefore, the use of such combinations is not recommended.
• Caution should be exercised when Tadalafil is administered to patients with anatomical deformation of the penis.
• Patients who suffer from problems that increase the possibility of Priapism (sickle-cell anemia, multiple myeloma, leukemia) should use this product with caution.
The following groups of patients with cardiovascular disease were not included in clinical trials and the use of Tadalafil is therefore contra-indicated:
• Patients with myocardial infarction within the last 90 days.
• Patients with unstable angina or angina occurring during sexual intercourse.
• Patients with uncontrolled arrhythmias, hypotension (<90/50 mmHg) or uncontrolled hypertension.
• Patients with a stroke within the last 6 months.
Although specific interactions have not been studied, some protease inhibitors, such as ritonavir and saquinavir, and other CYP3A4 inhibitors, such as erythromycin, clarithromycin, itraconazole and grapefruit juice, should be co-administered with caution as they would be expected to increase plasma concentrations of Tadalafil. Concomitant administration of other CYP3A4 inducers, such as rifampicin, Phenobarbital, phenytoin and carbamazepine, will also decrease plasma concentrations of Tadalafil.
Effects of tadalafil on other medicinal products
In clinical studies, Tadalafil (10 mg) was shown to augment the hypotensive effects of nitrates. Therefore, administration of Tadalafil to patients who are using any form of organic nitrate is contra-indicated. Tadalafil (10 mg) had no clinically significant effect on the plasma concentration of warfarin, nor did Tadalafil affect changes in prothrombin time induced by warfarin. Tadalafil (10 mg) did not potentiate the increase in bleeding time caused by acetylsalicylic acid. In clinical pharmacology studies, the potential for Tadalafil to augment the hypotensive effects of antihypertensive agents was examined. Concomitant administration of Tadalafil with the major classes of antihypertensive agents were studied, including calcium channel blockers (amlodipine),angiotensin converting enzyme (ACE)inhibitors (enalapril),beta-adrenergic receptor blockers (metoprolol),thiazide diuretics (bendrofluazide),and angiotensin II receptor blockers, did not affect the hypotensive effect of these drugs .Tadalafil (10 mg,except for studies with angiotensin II receptor blockers and amlodipine in which a 20 mg dose was applied) had no clinically significant interaction with any of these classes. No changes in Tadalafil concentrations were seen 3 hours after co-administration with alcohol. When Tadalafil 10 mg was administered with theophylline in a clinical pharmacology study, there was no pharmacokinetic interaction. The only pharmacodynamic effect was a small increase in heart rate. Specific interaction studies with antidiabetic agents were not conducted.